IP Library › Granted Patent US 12,653,714
Granted Patent B1
US 12,653,714 · App. 19/533,080 · Granted Jun 16, 2026

Systems and methods for endothelial regeneration of schlemm's canal

Inventor: Michael Reynard (Santa Monica, CA)
A61F9/0017A61F9/007A61M25/0045A61M2025/0057A61M2202/0007A61M2202/097A61M2205/0238A61M2205/3306A61M2205/3327A61M2210/0612
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,714
App. No.
19/533,080
Granted
Jun 16, 2026
Kind
B1
Abstract

The present disclosure provides systems, methods, and compositions for delivering endothelial cells into Schlemm's canal to restore physiological outflow in glaucoma and other ocular disorders. The document encompasses diverse devices and hydrogel carriers suitable for delivering endothelial cells, including conduits, microcatheters, scaffolds, stents, support devices, Schlemm's canal expanders, viscodilation balloons, tensioning sutures, hydrogel sleeves, and injectable formulations. The endothelial cells may be combined with extracellular matrix components, drugs, or growth factors, and may be delivered using controlled-release hydrogels to ensure uniform circumferential seeding. The system enables removal of dysfunctional Schlemm's canal endothelial cells, OCT/OCTA-guided functional analysis, and re-endothelialization via bioengineered scaffolds. Embodiments further integrate artificial intelligence for intraoperative guidance, predictive analytics, and postoperative monitoring of endothelial integration. Safe dosing strategies are disclosed to avoid canal obstruction, and commercial applications include combination biologic-device products and digital health solutions.

Claims (19)

1 . A device comprising:

a catheter, configured for insertion into an incision providing access to Schlemm's canal of an eye; and

a tubular hydrogel sleeve positioned around a distal shaft of the catheter, the tubular hydrogel sleeve comprising Schlemm's canal endothelial cells.

2 . The device of claim 1 , wherein the incision is in a cornea.

3 . The device of claim 1 , wherein the tubular hydrogel sleeve comprises polyethylene glycol (PEG).

4 . The device of claim 1 , wherein the tubular hydrogel sleeve comprises collagen.

5 . The device of claim 1 , wherein the tubular hydrogel sleeve comprises glucose.

6 . The device of claim 1 , wherein the tubular hydrogel sleeve comprises nitinol.

7 . The device of claim 1 , wherein the tubular hydrogel sleeve comprises nanopores.

8 . The device of claim 1 , further comprising a lumen configured to deliver a viscoelastic through the catheter.

9 . A device comprising:

a catheter, configured for insertion into an incision providing access to Schlemm's canal of an eye; and

a hydrogel coating bonded to a surface of a distal shaft of the catheter, the hydrogel coating comprising Schlemm's canal endothelial cells.

10 . The device of claim 9 , wherein the incision is in a sclera.

11 . The device of claim 9 , wherein the hydrogel coating comprises hyaluronic acid.

12 . The device of claim 9 , wherein the hydrogel coating comprises alginate.

13 . The device of claim 9 , further comprising a lumen configured to deliver a viscoelastic through the catheter.

14 . The device of claim 1 , wherein the tubular hydrogel sleeve includes hyaluronic acid.

15 . The device of claim 9 , wherein the hydrogel coating comprises polyethylene glycol (PEG).

Continuity (1)
Division 19348908 · Oct 3, 2025
References Cited (67)
US 4655771A · Wallsten · 1987 [cited by applicant]
US 5478338A · Reynard · 1995 [cited by applicant]
US 5558669A · Reynard · 1996 [cited by applicant]
US 5899517A · Murawa et al. · 1999 [cited by applicant]
US 6140127A · Sprague · 2000 [cited by applicant]
US 6428501B1 · Reynard · 2002 [cited by applicant]
US 8439972B2 · Badawi et al. · 2013 [cited by applicant]
US 8540659B2 · Berlin · 2013 [cited by applicant]
US 8894603B2 · Badawi et al. · 2014 [cited by applicant]
US 9510973B2 · Wardle · 2016 [cited by applicant]
US 9642746B2 · Berlin · 2017 [cited by applicant]
US 10154924B2 · Clauson et al. · 2018 [cited by applicant]
US 10485701B2 · Haffner et al. · 2019 [cited by applicant]
US 10517769B2 · Wood · 2019 [cited by applicant]
US 10993840B2 · Berlin · 2021 [cited by applicant]
US 11058584B2 · Berlin · 2021 [cited by applicant]
US 11090188B2 · Badawi et al. · 2021 [cited by applicant]
US 11116660B2 · Badawi et al. · 2021 [cited by applicant]
US 11135088B2 · Wardle et al. · 2021 [cited by applicant]
US 11259961B2 · Ianchulev · 2022 [cited by applicant]
US 11344477B2 · Kahraman et al. · 2022 [cited by applicant]
US 11389327B2 · Badawi et al. · 2022 [cited by applicant]
US 11389328B2 · Badawi et al. · 2022 [cited by applicant]
US 11419762B2 · Ianchulev · 2022 [cited by applicant]
US 11504270B1 · Badawi et al. · 2022 [cited by applicant]
US 11540940B2 · Noda et al. · 2023 [cited by applicant]
US 11857460B2 · Badawi et al. · 2024 [cited by applicant]
US 11872158B2 · Badawi et al. · 2024 [cited by applicant]
US 11872954B2 · Neubauer · 2024 [cited by applicant]
US 11938058B2 · Schieber et al. · 2024 [cited by applicant]
US 11951037B2 · Badawi et al. · 2024 [cited by applicant]
US 12016796B2 · Schieber et al. · 2024 [cited by applicant]
US 12042428B2 · Badawi et al. · 2024 [cited by applicant]
US 12213914B2 · Badawi et al. · 2025 [cited by applicant]
US 12274640B1 · Reynard · 2025 [cited by applicant]
US 12310891B2 · Badawi et al. · 2025 [cited by applicant]
US 12310892B2 · Ianchulev et al. · 2025 [cited by applicant]
US 12336933B2 · Noda et al. · 2025 [cited by applicant]
US 12350192B2 · Badawi et al. · 2025 [cited by applicant]
US 20020013456A1 · Sutcliffe et al. · 2002 [cited by applicant]
US 20020169130A1 · Tu · 2002 [cited by examiner]
US 20050220843A1 · DeWitt · 2005 [cited by examiner]
US 20070191863A1 · De Juan · 2007 [cited by examiner]
US 20090138070A1 · Holzer · 2009 [cited by examiner]
US 20100185156A1 · Kanner · 2010 [cited by examiner]
US 20140296800A1 · Erickson · 2014 [cited by examiner]
US 20140323995A1 · Clauson · 2014 [cited by examiner]
US 20180036065A1 · Yates et al. · 2018 [cited by applicant]
US 20190017017A1 · Xie · 2019 [cited by examiner]
US 20190117459A1 · Berlin · 2019 [cited by applicant]
US 20200188173A1 · Berlin · 2020 [cited by applicant]
US 20200281766A1 · Berlin · 2020 [cited by applicant]
US 20210386584A1 · Badawi et al. · 2021 [cited by applicant]
US 20220104967A1 · Badawi et al. · 2022 [cited by applicant]
US 20220104968A1 · Badawi et al. · 2022 [cited by applicant]
US 20220280339A1 · Badawi et al. · 2022 [cited by applicant]
US 20220280340A1 · Badawi et al. · 2022 [cited by applicant]
US 20230080761A1 · Taylor · 2023 [cited by examiner]
US 20240366424A1 · Badawi et al. · 2024 [cited by applicant]
CN 102971030 · 2013 [cited by examiner]
WO WO9211896A1 · 1992 [cited by examiner]
WO 03045290A1 · 2003 [cited by applicant]
WO 2006066103A2 · 2006 [cited by applicant]
WO 2022062050A1 · 2022 [cited by applicant]
Charters, L. (Jun. 1, 2023). A closer look at how cell therapy for corneal endothelial disease is gaining traction | ophthalmology times europe. Ophthalmology Times Europe. (Year: 2023). [cited by examiner]
Blache U, Ehrbar M. Inspired by Nature: Hydrogels as Versatile Tools for Vascular Engineering. Adv Wound Care (New Rochelle). Jul. 1, 2018;7(7):232-246. doi: 10.1089/wound.2017.0760. PMID: 29984113; PMCID: PMC6032659 (Y… [cited by examiner]
Carol W Chen,et al. Sustained release of endothelial progenitor cell-derived extracellular vesicles from shear-thinning hydrogels improves angiogenesis and promotes function after myocardial infarction, Cardiovascular R… [cited by examiner]